Cited 0 times in
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.contributor.author | 조재용 | - |
dc.date.accessioned | 2021-12-28T16:44:04Z | - |
dc.date.available | 2021-12-28T16:44:04Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186777 | - |
dc.description.abstract | Background: ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with ≥ 2 chemotherapy regimens. However, its long-term efficacy and outcome of treatment beyond progression (TBP) with nivolumab have not been clarified. Methods: The 3-year follow-up data were collected. A subset analysis was performed to explore the efficacy of TBP by assessing postprogression survival (PPS) after the first event of disease progression. Results: Overall, 493 patients were randomized (2:1) to receive nivolumab (n = 330) or placebo (n = 163). With a median follow-up of 38.5 (range 36.1-47.5) months, OS of the nivolumab group was significantly longer compared to the placebo group (median 5.3 vs 4.1 months; 3-year survival rate, 5.6% vs 1.9%; hazard ratio [HR], 0.62 [95% confidence interval (CI) 0.50-0.75], P < 0.0001). The median OS of responders (n = 32) who achieved complete response or partial response was 26.7 months and the 3-year survival rate was 35.5% in the nivolumab group. Overall, 109 patients in the nivolumab group and 37 patients in the placebo group received TBP. PPS tended to be longer in the nivolumab group vs placebo group (median 5.8 vs 4.5 months; HR [95% CI], 0.69 [0.47-1.01], P = 0.057). In contrast, PPS was similar between both treatment groups in non-TBP patients (median 2.3 vs 2.2 months; HR 0.90, P = 0.42). Conclusions: Long-term efficacy of nivolumab was confirmed at the 3-year follow-up, and a survival benefit of TBP with nivolumab was suggested. Biomarkers for selecting patients suitable for TBP with nivolumab should be identified in the future. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Springer-Verlag Tokyo | - |
dc.relation.isPartOf | GASTRIC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Narikazu Boku | - |
dc.contributor.googleauthor | Taroh Satoh | - |
dc.contributor.googleauthor | Min-Hee Ryu | - |
dc.contributor.googleauthor | Yee Chao | - |
dc.contributor.googleauthor | Ken Kato | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Jen-Shi Chen | - |
dc.contributor.googleauthor | Kei Muro | - |
dc.contributor.googleauthor | Won Ki Kang | - |
dc.contributor.googleauthor | Kun-Huei Yeh | - |
dc.contributor.googleauthor | Takaki Yoshikawa | - |
dc.contributor.googleauthor | Sang Cheul Oh | - |
dc.contributor.googleauthor | Li-Yuan Bai | - |
dc.contributor.googleauthor | Takao Tamura | - |
dc.contributor.googleauthor | Keun-Wook Lee | - |
dc.contributor.googleauthor | Yasuo Hamamoto | - |
dc.contributor.googleauthor | Jong Gwang Kim | - |
dc.contributor.googleauthor | Keisho Chin | - |
dc.contributor.googleauthor | Do-Youn Oh | - |
dc.contributor.googleauthor | Keiko Minashi | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.contributor.googleauthor | Masahiro Tsuda | - |
dc.contributor.googleauthor | Taihei Nishiyama | - |
dc.contributor.googleauthor | Li-Tzong Chen | - |
dc.contributor.googleauthor | Yoon-Koo Kang | - |
dc.identifier.doi | 10.1007/s10120-021-01173-w | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J00916 | - |
dc.identifier.eissn | 1436-3305 | - |
dc.identifier.pmid | 33743112 | - |
dc.subject.keyword | ATTRACTION-2 | - |
dc.subject.keyword | Gastric or gastroesophageal junction cancer | - |
dc.subject.keyword | Long-term efficacy | - |
dc.subject.keyword | Nivolumab | - |
dc.subject.keyword | Treatment beyond progression | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.contributor.affiliatedAuthor | 조재용 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 946 | - |
dc.citation.endPage | 958 | - |
dc.identifier.bibliographicCitation | GASTRIC CANCER, Vol.24(4) : 946-958, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.